Martins JO, Borges MM, Malta CE, Guerra JM, Crispim AA, Coelho BC, et al. Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study. Med Oral Patol Oral Cir Bucal. 2024 Mar 1;29 (2):e248-54.
doi:10.4317/medoral.26237
https://dx.doi.org/doi:10.4317/medoral.26237
1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237-21. |
PMid:22437869 PMCid:PMC3967236 |
2. Kimiz-gebologlu I, Gulce-iz S, Biray-avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018;45:2935-40. |
PMid:30311129 |
3. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs. 2020;80:797-811 |
PMid:32333236 PMCid:PMC7242277 |
4. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;395:784. |
PMid:30449625 |
5. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzoet S. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 2010;10:80. |
PMid:20088790 |
6. Mazzarella L, Guida A, Curigliano G. Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2018;18:483-93. |
PMid:29534625 |
7. Moon C, Chae YK, lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med. 2010;235:907-20. |
PMid:20562132 |
8. Daugėlaitė G, Užkuraitytė K, Jagelavičienė E, Filipauskas A. Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis. Medicina. 2019;55:25. |
PMid:30678228 PMCid:PMC6410239 |
9. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58:341-9. |
PMid:24655526 |
10. Pulito C, Cristaudo A, La Porta A, Zapperi S, Blandino G, Morrone A, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020;39:1-15. |
PMid:33028357 PMCid:PMC7542970 |
11. Elyasi S, Hosseini S, Moghadam MRN, Aledavood SA, Karimi G. Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: A randomized, double‐blinded, placebo‐controlled clinical trial. Phytother Res. 2016;30:1879-85. |
PMid:27555604 |
12. Holt MH, Liu V, Fairley J. Medium-vessel vasculitis presenting as multiple leg ulcers after treatment with abatacept. JAAD Case Rep. 2018;4:811-3. |
PMid:30246135 PMCid:PMC6141677 |
13. Malta M, Cardoso LO, Bastos FI, Magnanini MMF, Silva CMFP. STROBE initiative: guidelines on reporting observational studies. Rev Saúde Pub. 2010;44:559-65. |
PMid:20549022 |
14. Treanor CJ, McMenamin UC, O'Neill RF, Cardwell CR, Clarke MJ, Cantwell M, et al. Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. Cochrane Database Syst Ver. 2016;2016:CD011325. |
PMid:27529826 PMCid:PMC8734151 |
15. Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T, et al. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib. Biol Pharm Bull. 2022;45:333-8. |
PMid:35228399 |
16. Meads C, Round J, Tubeuf S, Moore D, Pennant M, Baylisset S. Cetuximab for the first-line treatment of metastatic colorectal cancer. Health Technol Assess. 2010;14:1-8. |
PMid:20507797 |
17. Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257. |
PMid:22712026 PMCid:PMC3376776 |
18. Mei M, Chen YH, Meng T, Qu LH, Zhang ZY, Zhang X. Comparative efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data. Ther Adv Med Oncol. 2020;12:1-10. |
PMid:33343720 PMCid:PMC7727048 |
19. Alongi F, Bignardi M, Garassino I, Pentimalli S, Cavina R, Mancosu P, et al. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Strahlenthe Onkol. 2012;188:49-55. |
PMid:22194030 |
20. Peña-cardelles JF, Salgado-Peralvo AO, Garrido-Martínez P, Cebrián-Carretero JL, Pozo-Kreilinger JJ, Moro-Rodríguez JE. Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review. Med Oral Patol Oral Cir Bucal. 2021;1:243-53. |
PMid:33772569 PMCid:PMC8254888 |
21. Soutome S, Yanamoto S, Nishii M, Kojima Y, Hasegawa T, Funahara M, et al. Risk factors for severe radiation-induced oral mucositis in patients with oral cancer. J Dent Sci. 2021;16:1241-6. |
PMid:34484592 PMCid:PMC8403800 |
22. Dote S, Itakura S, Kamei K, Hira D, Noda S, Kobayashi Y, et al. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. BMC Cancer. 2018;18:1-7. |
PMid:30290786 PMCid:PMC6173836 |
23. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29:3419-26. |
PMid:21810686 |
24. Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, et al. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2014;25:424-7. |
PMid:23167307 |
25. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78. |
PMid:16467544 |
26. Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011;98:38-41. |
PMid:21159400 |
27. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-27. |
PMid:18784101 |
28. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25:2191-7. |
PMid:17538164 |
29. Li J, Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol. 2018;82:571-83. |
PMid:30006755 |
30. Vokurka S, Bystrická E, Koza V, Scudlová J, Pavlicová V, Valentová D, et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer. 2006;14:974-6. |
PMid:16502004 |